Get my own profile
Public access
View all29 articles
4 articles
available
not available
Based on funding mandates
Co-authors
- Allan JordanVice President of Oncology Drug Discovery, Sygnature DiscoveryVerified email at thejordans.org.uk
- Dominic JamesImagen TherapeuticsVerified email at imagentherapeutics.com
- Emma FairweatherBiochemical assay development and screeningVerified email at liverpool.ac.uk
- Nicola HamiltonRedx Pharma PlcVerified email at redxpharma.com
- Mandy WatsonCRUK Manchester InstituteVerified email at cruk.manchester.ac.uk
- Daniel Mould, PhDActuary, K3 AdvisoryVerified email at cruk.manchester.ac.uk
- Michael B. ReidDean & Professor, University of FloridaVerified email at ufl.edu
- Julie TuckerUniversity of YorkVerified email at york.ac.uk
- Robert J Schwartzuniversity of HoustonVerified email at uh.edu
- Matthew CoghlanSenior Advisor, Eli Lilly and CompanyVerified email at lilly.com
- Ryan G KrugerAnagenexVerified email at anagenex.com
- Juan I LuengoVP of Drug Discovery Research, Prelude TherapeuticsVerified email at preludetx.com
- Professor Neil Q. McdonaldSenior Group Leader, The Francis Crick InstituteVerified email at crick.ac.uk
- Mark J O'ConnorAstraZeneca Oncology UKVerified email at astrazeneca.com
- Christopher J MorrowAstraZenecaVerified email at astrazeneca.com
- Peter WarnerSPO, Bill & Melinda Gates FoundationVerified email at gatesfoundation.org
- Mark CockerillCancer Research UK